(6832217), M. F. A., (6833627), M. L., (133780), D. C., (5234345), S. G., (15267632), L. A., (14085594), H. A. H., . . . (111321), J. G. W. (2023). Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: A model-based cost-utility analysis of data from CONSTRUCT pragmatic trial.
Chicago Style (17th ed.) Citation(6832217), Mohammed Fasihul Alam, Mirella Longo (6833627), David Cohen (133780), Sam Groves (5234345), Laith Alrubaiy (15267632), Hayley A. Hutchings (14085594), Alan Watkins (432126), Shaji Sebastain (15267635), and John G. Williams (111321). Infliximab Versus Ciclosporin in Steroid Resistant Acute Severe Ulcerative Colitis: A Model-based Cost-utility Analysis of Data from CONSTRUCT Pragmatic Trial. 2023.
MLA (9th ed.) Citation(6832217), Mohammed Fasihul Alam, et al. Infliximab Versus Ciclosporin in Steroid Resistant Acute Severe Ulcerative Colitis: A Model-based Cost-utility Analysis of Data from CONSTRUCT Pragmatic Trial. 2023.